Replimune Group (NASDAQ:REPL) announced its earnings results on Monday. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.01), Bloomberg Earnings reports.
Shares of Replimune Group stock traded down $0.02 on Tuesday, hitting $17.19. The company had a trading volume of 108 shares, compared to its average volume of 99,711. The stock has a market capitalization of $535.79 million, a price-to-earnings ratio of -12.89 and a beta of 3.30. Replimune Group has a 1 year low of $8.88 and a 1 year high of $18.25. The stock has a 50 day moving average of $14.61 and a 200-day moving average of $13.46.
In related news, CEO Robert Coffin sold 24,250 shares of the stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $17.05, for a total transaction of $413,462.50. Also, COO Colin Love sold 11,250 shares of the stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $17.05, for a total value of $191,812.50. Over the last three months, insiders sold 200,000 shares of company stock valued at $3,395,500. Company insiders own 63.18% of the company’s stock.
Several brokerages have issued reports on REPL. ValuEngine upgraded Replimune Group from a “sell” rating to a “hold” rating in a report on Monday, November 4th. Zacks Investment Research downgraded Replimune Group from a “buy” rating to a “hold” rating in a research note on Saturday, October 26th. HC Wainwright reissued a “buy” rating and issued a $26.00 price objective on shares of Replimune Group in a research note on Monday, September 30th. Chardan Capital reissued a “buy” rating and issued a $28.00 price objective on shares of Replimune Group in a research note on Thursday, October 24th. Finally, Roth Capital increased their price objective on Replimune Group from $20.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $25.17.
Replimune Group Company Profile
Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.
Featured Article: What is a stock split?
Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.